Abiopharma

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

XORTX Initiates IND Preparation for XORLO™ in Gout Program

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

New Form 6-K - GSK plc Filed: 2025-09-03 AccNo: 0001654954-25-010336 Size: 2 MB

New Form 8-K - Chemours Co Filed: 2025-09-03 AccNo: 0000950170-25-112670 Size: 247 KB Item 8.01: Other Events

Chemours Announces Board Leadership Appointments: Mary Cranston Named Chair, Alister Cowan Named Lead Independent Director

New Form 6-K - Haleon plc Filed: 2025-09-03 AccNo: 0001654954-25-010334 Size: 37 KB

Grey symbol attribute type Security_Name was changed. Previous value: NTT DC REIT MANAGER REIT. New value: ONTRAK INC 9.50% A PFD.

General Announcement: ANNOUNCEMENT ON CONVENING AN ONLINE CONFERENCE

New Form S-3/A - Tharimmune, Inc. Filed: 2025-09-03 AccNo: 0001641172-25-026303 Size: 152 KB

New Form 8-K - STANDARD BIOTOOLS INC. Filed: 2025-09-03 AccNo: 0000950170-25-112662 Size: 194 KB Item 2.05: Cost Associated with Exit or Disposal Activities

New Form DEFR14A - BioSig Technologies, Inc. Filed: 2025-09-03 AccNo: 0001641172-25-026300 Size: 29 KB

New Form EFFECT - BRIGHT MINDS BIOSCIENCES INC. Filed: 2025-09-02 AccNo: 9999999995-25-002807 Size: 1 KB

New Form EFFECT - Galmed Pharmaceuticals Ltd. Filed: 2025-09-02 AccNo: 9999999995-25-002804 Size: 1 KB

New Form EFFECT - ACCURAY INC Filed: 2025-09-02 AccNo: 9999999995-25-002800 Size: 1 KB